Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer: a subgroup analysis of the finnish RAXO study

Kontiainen, Joel; Lehtomäki, Kaisa; Muhonen, Timo; Heervä, Eetu; Ålgars, Annika; Ristamäki, Raija; Stedt, Hanna; Lamminmäki, Annamarja; Kallio, Raija; Salminen, Tapio; Kuopio, Teijo; Osterlund, Emerik; Aho, Sonja; Bärlund, Maarit; Halonen, Päivi; Soveri, Leena-Maija; Nordin, Arno; Uutela, Aki; Glimelius, Bengt; Isoniemi, Helena; Osterlund, Pia

Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer: a subgroup analysis of the finnish RAXO study

Kontiainen, Joel
Lehtomäki, Kaisa
Muhonen, Timo
Heervä, Eetu
Ålgars, Annika
Ristamäki, Raija
Stedt, Hanna
Lamminmäki, Annamarja
Kallio, Raija
Salminen, Tapio
Kuopio, Teijo
Osterlund, Emerik
Aho, Sonja
Bärlund, Maarit
Halonen, Päivi
Soveri, Leena-Maija
Nordin, Arno
Uutela, Aki
Glimelius, Bengt
Isoniemi, Helena
Osterlund, Pia
Katso/Avaa
Disease-phase-specific resource utilization and healthcare costs in metastatic colorectal cancer a subgroup analysis of the finnish RAXO study.pdf (1.655Mb)
Lataukset: 

Taylor and Francis Group
doi:10.1080/00365521.2025.2594779
URI
https://doi.org/10.1080/00365521.2025.2594779
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe202601216795
Tiivistelmä

Introduction

Metastatic colorectal cancer (mCRC) represents a growing burden on healthcare, yet comprehensive data on treatment costs across different disease phases remain limited. This study aims to estimate hospital resource utilization and costs of treating mCRC patients according to international up-to-date guidelines.

Materials and methods

The RAXO study aimed at maximising metastasectomy with repeated centralized assessment of resectability (inclusion 2012–2018). Cost data from the six largest Finnish hospital districts (n = 941) in RAXO were collected from mCRC diagnosis to death or the end of 2021. All patient costs were characterized day-by-day to diagnostic, curative, remission, palliative SACT, treatment break, or end-of-life disease phases. The resource utilization and mean costs, in 2021 euros, were calculated per patient per month (PPPM).

Results

The mean PPPM cost for treating mCRC patients was 2323€, when 37% had curative-intent metastasectomy. On average, each month included 0.7 ward days, 1.9 outpatient and 0.1 emergency visits. Outpatient care accounted for 64% of costs, inpatient care for 34%, and emergency room visits for 2%. The higher costs during disease phases involving active tumour-directed treatments (2963€–3059€/PPPM) were balanced by lower costs during remission and treatment break (453€–560€/PPPM). Pharmacy, ward, operating room, and outpatient costs (39%/18%/15%/15%, respectively) were the main drivers for internal hospital billing.

Conclusions

Resource utilization, costs, and cost drivers varied 8-fold between disease phases. Outpatient care accounted for two-thirds, and inpatient care accounted for one-third of costs.

Kokoelmat
  • Rinnakkaistallenteet [29337]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste